Invest1 publisher3 min readPublished
Blackstone shops ZO Skin Health at double the top price e.l.f. agreed for Rhode
Reuters reports Blackstone is exploring a sale of ZO Skin Health at around $2 billion. The dermatologist-channel brand's strongest disclosed figure is the share of patients who bought it twice in 2025.
The Investor · Invest desk
What happened
- Blackstone is exploring a sale of ZO Skin Health at a valuation of around $2 billion, Reuters reported, citing people familiar with the matter.
- Nearly 40% of ZO customers at medical-aesthetics practices made a repeat purchase in 2025, the highest patient-retention rate among leading professional-grade skincare brands, according to Guidepoint Qsight.
- ZO's protocols are paired with lasers, chemical peels and microneedling, and the company supplies protocol training, staff education and launch support to practices, according to Med Spa Vendor Hub.
Compiled by The InvestorSomething wrong?How this is made
Why it matters
- contradiction Fortune's channel sources point opposite ways: Qsight's transaction data ranks ZO first on repeat purchase, while a SkinSpirit nurse says its pricing and provider incentives match every other professional brand the clinic carries. A bidder has to decide which of those two accounts it is paying for.
- constraint The restricted distribution that protects ZO's premium pricing also narrows what a new owner can do with the brand: a push back onto department-store or specialty retail shelves would cut against the physician economics ZO has been paying for since 2012.
- exposure The retention a buyer would be paying for sits inside independent practices whose staff ZO trains, and four rival brands are already in the same rooms. A rival with a better commission schedule can reach ZO's replenishment revenue and leave the brand where it is.
- precedent A clearing price near $2 billion for a brand sold only through its own site and authorized providers would become the reference point the next professional-skincare seller cites.
Divide Coty's $600 million by the 51% it bought and Kylie Cosmetics prices at about $1.18 billion whole [2]. The $2 billion Reuters reports for ZO is roughly 1.7 times that [2], and about 4.4 times the $450 million Shiseido paid for Dr. Dennis Gross Skincare [3]. Against Rhode it is about double [1], measured against a ceiling, because e.l.f. agreed to pay up to $1 billion [2]. Blackstone did not disclose ZO's revenue or what it paid for the brand.
What a bidder buys, on the record, is an arrangement ZO began building in 2012, when it launched physician affiliate and revenue-sharing programs that let participating doctors earn commissions when patients replenished through physician-linked virtual stores [6]. The brand started at Nordstrom in 2007 and moved off department-store shelves toward physicians [5]. Sales now run through the official website and authorized providers, and some prescription products require a physician [7]. ZO says it works to minimize unauthorized sales "to protect our customers, along with the integrity of our trusted physician partners' businesses" [8].
Guidepoint Qsight's 2026 report draws on transaction data covering more than $17 billion in verified patient spending from thousands of US aesthetics practices [11]. In it, about four in ten ZO patients at medical-aesthetics practices bought the brand again during 2025 [4].
Rivals work the same channel. L'Oreal-owned SkinCeuticals, AbbVie's SkinMedica, Skinbetter Science and Alastin all court dermatologists and medical-aesthetics practices with their own professional distribution and provider-support programs [12]. Roxette Romanes, an aesthetic nurse specialist at SkinSpirit's Roslyn Heights location, said of ZO's economics: "Everyone is pretty on par on prices. I don't think there's a skin care brand that is more or less. They are pretty similar regarding pricing" [13]. She added, "Other than getting the sales from the actual skin care, I don't think there's more incentive than that" [14].
Some of the demand starts outside the treatment room. Dr. Jeffrey Lisiecki, a board-certified New York City plastic surgeon, said "I get requests for their sunscreen all the time" [15], and that "a lot of patients know of it and ask about it sometimes even before I've given someone their post-operative skincare regimen" [16]. That is consumer recognition, which is the thing e.l.f. agreed to pay up to $1 billion for in Rhode [2].
So the sale prices two ways. If the buyer is underwriting the physician channel, it is paying for a commission schedule four named rivals already run [12], and Romanes's account says the incentives are level [14]. If it is underwriting recognition plus the repeat rate, it is buying the same asset class as Rhode with a clinic channel attached and, per Qsight, the best retention in the professional category [10]. In my view the second reading is the only one that carries $2 billion; what would break it is a later Qsight report showing ZO's repeat purchase rate converging on SkinCeuticals, SkinMedica, Skinbetter and Alastin.
What to watch
- Whether Blackstone's exploration produces a buyer near $2 billion or the process is shelved without a sale.
- Whether a strategic owner of a rival professional brand bids, given L'Oreal owns SkinCeuticals and AbbVie owns SkinMedica.
- Whether a rival lifts provider commissions at the practices ZO's revenue-sharing programs have paid since 2012.